Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blinded, Multicenter Study in Healthy Adults to Evaluate Safety and Immunogenicity of AV7909 Administered at Two Dose Levels on Two Vaccination Schedules, Including a Primary Series and Booster Doses
Conditions
Interventions
AV7909 Full Dose (0.5 mL)
AV7909 Half Dose (0.25 mL)
+2 more
Locations
7
United States
Accellacare of Hickory
Hickory, North Carolina, United States
Accellacare of Salisbury
Salisbury, North Carolina, United States
Accellacare of Piedmont
Statesville, North Carolina, United States
Accellacare of Winston-Salem
Winston-Salem, North Carolina, United States
Accellacare Knoxville
Jefferson City, Tennessee, United States
Accellacare Knoxville
Knoxville, Tennessee, United States
Start Date
December 5, 2023
Primary Completion Date
August 28, 2025
Completion Date
August 1, 2026
Last Updated
February 24, 2026
NCT00050310
NCT03569514
NCT07268612
NCT04067011
NCT04660201
NCT05672875
Lead Sponsor
Biomedical Advanced Research and Development Authority
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions